Oscar Health Beats Expectations With Record Profits and Raises 2026 Outlook
Membership near 3M as medical costs ease and outlook rises.
/ 1648 items
#XY↓
Moderna’s mFlusiva Becomes First mRNA Flu Shot Cleared by FDA
FDA approves mFlusiva, Moderna’s first mRNA flu vaccine for adults 50+. Available soon for the 2026 season with strong trial results.
Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines
TYRA shares fell after Q2 results showed delayed BEACH301 and SURF302 data, a wider $45.6M loss, and potential dilution from a new $250M ATM.
Insulet Shares Plunge After Cutting 2026 Sales Forecast on Slower U.S. Omnipod Growth
Insulet lowered its full-year sales outlook, citing weaker U.S. Omnipod demand and lower retention among type 2 diabetes users. The news heightens scrutiny on peers in the insulin pump and CGM space.
CVS Beats Q2 Expectations and Raises 2026 Guidance, But Shares Drop on Soft 2027 Outlook
CVS Health reports strong Q2 results with $2.58 adjusted EPS and raises 2026 guidance, but shares fall on a muted 2027 outlook and cautious cost warnings.
Compass Pathways Shares Jump on Strong COMP360 Phase 3 Data and Clear Path to 2027 Launch
Compass Pathways reports strong Q2: Phase 3 wins for COMP360 in TRD, $433M cash, rolling NDA, and commercial launch planned for first half 2027.